Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 50 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

24%

12 trials in Phase 3/4

Results Transparency

0%

0 of 29 completed trials have results

Key Signals

8 recruiting

Enrollment Performance

Analytics

Phase 1
35(70.0%)
Phase 3
12(24.0%)
Phase 2
3(6.0%)
50Total
Phase 1(35)
Phase 3(12)
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (50)

Showing 20 of 50 trials
NCT07550231Phase 2Not Yet Recruiting

Determining the Optimal Dose of AD-211 in Patients With Osteoarthritis of the Knee

Role: lead

NCT07538466Phase 1Not Yet Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Role: lead

NCT07521241Phase 1Not Yet Recruiting

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Role: lead

NCT07495514Phase 1Enrolling By Invitation

A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers

Role: lead

NCT07476157Phase 1Not Yet Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects

Role: lead

NCT07444385Phase 1Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

Role: lead

NCT07385248Phase 1Not Yet Recruiting

A Clinical Trial to Assess the Pharmacokinetics and Safety of AD-229 Compared to AD-2291 in Healthy Adults

Role: lead

NCT07385235Phase 1Recruiting

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Role: lead

NCT07312799Phase 1Not Yet Recruiting

Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322

Role: lead

NCT07312773Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-231A and AD-231B and AD-231C

Role: lead

NCT07152873Phase 1Not Yet Recruiting

A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A

Role: lead

NCT06884085Phase 1Completed

A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

Role: lead

NCT06902818Phase 1Completed

The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

Role: lead

NCT07103278Phase 1Not Yet Recruiting

A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers

Role: lead

NCT06858865Phase 1Completed

A Study to Evaluate the Safety and Pharmacokinetics of AD-228A Compared to Coadministration of AD-2281 and AD-2282

Role: lead

NCT06976489Phase 1Not Yet Recruiting

The Food Effect on PK Characteristics and Safety Profiles of PA-111

Role: lead

NCT06932705Phase 1Recruiting

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

Role: lead

NCT06916130Phase 1Not Yet Recruiting

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

Role: lead

NCT06052748Phase 3Completed

A Study to Evaluate the Efficacy and Safety of AD-223

Role: lead

NCT06884098Phase 1Recruiting

A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Role: lead